Chart Your Course

APRIL 6, 2015

When that much of the workforce — 42% of women surveyed and 34% of men — feel they’re under-compensated for their work, employee motivation and performance suffer. Pharmaceutical and biotechnology make up the second-largest group with three representatives: Genentech, Amgen and Pfizer. Costco, at No.

White Paper 100

White Paper Company Biotechnology Case Study 100

Tanveer Naseer

MAY 16, 2011

Russell is an educational psychologist, author, executive coach and management consultant whose clients include Fortune 500 executives in aerospace, healthcare, pharmaceutical and biotechnology, information technology, telecommunications and oil and gas.

Bureaucracy 203

Bureaucracy Compliance Learning-by-Doing Engineering 203

Tanveer Naseer

JUNE 2, 2015

Dan was the president of a biotechnology company where I served in my first middle management role.

Biotechnology 100

Biotechnology Learning-by-Doing Audience Middle Management 100

Harvard Business Review

FEBRUARY 16, 2016

Different Industries, Different Regions, Different Motivations. To explore the various motivations underlying these concerns, we separated the responses of directors working in different industries. pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g.,

Politics 8

Politics Telecommunications Policies Biotechnology 8

Harvard Business Review

OCTOBER 23, 2014

That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. They’re also sharing risk. The new business model has yet to solidify, and the leaders have yet to emerge. The positions are there for the taking. But not for long.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Tanveer Naseer

OCTOBER 20, 2015

The first leader was someone I worked with as part of the management team at a biotechnology firm, and how he guided our organization during the merger of our North American parent company with a much larger European multinational.

Power 100

Power Long-term Uncertainty Biotechnology 100

Harvard Business Review

FEBRUARY 24, 2017

Given that there are many reasons why a bill might fail — and many people who might be able to prevent it from coming to a vote — it is hard to prove that a particular lawmaker is motivated by their investment holdings. Not only did his wife invest between $610,000 and $1.5

Conflict of Interest 8

Conflict of Interest Committee Collins Politics 8